62 related articles for article (PubMed ID: 2820176)
1. [Value of calcitonin and 6-oxo-prostaglandin Fl alpha in the differentiation of lung cancers].
Burghuber OC; Kovarik J; Woloszczuk W; Sehnal E; Sinzinger H; Weissel M
Acta Med Austriaca; 1987; 14(2):47-50. PubMed ID: 2820176
[TBL] [Abstract][Full Text] [Related]
2. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
[TBL] [Abstract][Full Text] [Related]
3. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
4. Increased plasma-6-oxo-PGF1-alpha but normal PGI2 half-life in patients with maxillo-facial tumors.
Porteder H; Matejka M; Kment G; Nell A; Sinzinger H
Prog Clin Biol Res; 1987; 242():123-9. PubMed ID: 3313409
[TBL] [Abstract][Full Text] [Related]
5. Plasma calcitonin as a marker of disease activity in patients with small cell carcinoma of the lung.
Wallach SR; Royston I; Taetle R; Wohl H; Deftos LJ
J Clin Endocrinol Metab; 1981 Sep; 53(3):602-6. PubMed ID: 6267098
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
7. [Calcitonin as a marker for bronchial carcinoma (author's transl)].
Gropp C; Havemann K; Pflüger KH
Dtsch Med Wochenschr; 1980 Aug; 105(34):1175-8. PubMed ID: 6257466
[TBL] [Abstract][Full Text] [Related]
8. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients.
McLemore TL; Hubbard WC; Litterst CL; Liu MC; Miller S; McMahon NA; Eggleston JC; Boyd MR
Cancer Res; 1988 Jun; 48(11):3140-7. PubMed ID: 3130187
[TBL] [Abstract][Full Text] [Related]
9. Prostacyclin concentrations in cord blood and in the newborn.
Jacqz EM; Barrow SE; Dollery CT
Pediatrics; 1985 Dec; 76(6):954-7. PubMed ID: 3906549
[TBL] [Abstract][Full Text] [Related]
10. [Biochemical methods and their place in prognosis and evaluation of the effectiveness of treatment of small cell lung cancer].
Bassalyk LS; Tkacheva GA; Ausekar BV; Smirnova KD; Gershteĭn ES
Vopr Onkol; 1985; 31(10):28-32. PubMed ID: 2998083
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
12. Association of serum reactive oxygen metabolite levels with different histopathological types of lung cancer.
Gencer M; Ceylan E; Aksoy N; Uzun K
Respiration; 2006; 73(4):520-4. PubMed ID: 16432293
[TBL] [Abstract][Full Text] [Related]
13. Prostacyclin and platelet aggregation in sickle cell disease.
Mehta P; Albiol L
Pediatrics; 1982 Sep; 70(3):354-9. PubMed ID: 6896748
[TBL] [Abstract][Full Text] [Related]
14. [Serum calcitonin concentration in patients with primary lung cancer].
Kozielski J; Sledziński Z; Kokot F
Pneumonol Pol; 1983 Dec; 51(12):627-32. PubMed ID: 6322139
[No Abstract] [Full Text] [Related]
15. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
16. High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung carcinoma: diagnostic value, relation to serum neuron specific enolase, and staging.
Dowlati A; Bury T; Corhay JL; Weber T; Mendes P; Radermecker M
Cancer; 1996 May; 77(10):2039-43. PubMed ID: 8640667
[TBL] [Abstract][Full Text] [Related]
17. Carcinoma of the lung with marked hyperamylasemia and elevated serum calcitonin.
Roberts I; Chopra S; Warshaw AL
Am J Gastroenterol; 1982 Jan; 77(1):43-4. PubMed ID: 6175207
[TBL] [Abstract][Full Text] [Related]
18. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
[TBL] [Abstract][Full Text] [Related]
19. [Radioimmunologic evaluation of the prognosis and effective therapy of patients with small cell lung cancer].
Ausekar BP6 ; Smirnova KD; Gromova NV; Perevodchikova NI
Med Radiol (Mosk); 1985 Nov; 30(11):18-20. PubMed ID: 2999553
[TBL] [Abstract][Full Text] [Related]
20. Cut-off levels of NSE to differentiate SCLC from NSCLC.
Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
